Scilex Holding Company (SCLX) announced on Thursday that the FDA has approved a Supplemental New Drug Application for label updates to Gloperba.Gloperba is notable for being the sole FDA-approved liquid formulation of colchicine meant for the prevention of acute gout flares. Given that over 70% of gout patients have chronic kidney disease and many experience gastrointestinal sensitivity, there is a growing need for a lower dosage alternative to the standard 0.6 mg tablet or capsule.This newly approved liquid formulation is anticipated to be the first to enable healthcare providers to prescribe precise dosing for at-risk patient populations, thereby helping to minimize the risk of severe toxicity.A market research study recently conducted by Scilex among rheumatologists indicated a high level of interest in Gloperba for its potential in precision dosing as a liquid colchicine formulation.The material has been provided by InstaForex Company – www.instaforex.com
- Air Canada And ALPA Reach Tentative Four-Year Agreement - September 15, 2024
- J&J’s TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer - September 15, 2024
- Saudi Arabia’s CPI Holds Steady at 0.1% for August, Defying Market Expectations - September 15, 2024
